Chest drain aerosol generation in COVID-19 and emission reduction using a simple anti-viral filter.
Aerosols
Betacoronavirus
COVID-19
Chest Tubes
Coronavirus Infections
/ transmission
Drainage
Filtration
/ instrumentation
Health Personnel
Humans
Infectious Disease Transmission, Patient-to-Professional
/ prevention & control
Occupational Exposure
/ prevention & control
Pandemics
Particle Size
Particulate Matter
Pneumonia, Viral
/ transmission
SARS-CoV-2
pleural disease
respiratory infection
thoracic surgery
viral infection
Journal
BMJ open respiratory research
ISSN: 2052-4439
Titre abrégé: BMJ Open Respir Res
Pays: England
ID NLM: 101638061
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
11
07
2020
revised:
27
08
2020
accepted:
07
10
2020
entrez:
5
11
2020
pubmed:
6
11
2020
medline:
18
11
2020
Statut:
ppublish
Résumé
The COVID-19 pandemic has been characterised by significant in-hospital virus transmission and deaths among healthcare workers. Sources of in-hospital transmission are not fully understood, with special precautions currently reserved for procedures previously shown to generate aerosols (particles <5 μm). Pleural procedures are not currently considered AGPs (Aerosol Generating Procedures), reflecting a lack of data in this area. An underwater seal chest drain bottle (R54500, Rocket Medical UK) was set up inside a 60-litre plastic box and connected via an airtight conduit to a medical air supply. A multichannel particle counter (TSI Aerotrak 9310 Aerosol Monitor) was placed inside the box, allowing measurement of particle count/cubic foot (pc/ft Aerosol emissions increased with increasing air flow, with the largest increase observed in smaller particles (0.3-3 μm). Concentration of the smallest particles (0.3-0.5 μm) increased from background levels by 700, 1400 and 2500 pc/ft A bubbling chest drain is a source of aerosolised particles, but emission can be prevented using a simple anti-viral filter. These data should be considered when designing measures to reduce in-hospital spread of SARS-CoV-2.
Identifiants
pubmed: 33148778
pii: 7/1/e000710
doi: 10.1136/bmjresp-2020-000710
pmc: PMC7643431
pii:
doi:
Substances chimiques
Aerosols
0
Particulate Matter
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: KGB has received research funding from Rocket Medical UK for other studies.
Références
Clin Med (Lond). 2020 Jul;20(4):e60-e61
pubmed: 32457134
Chest. 2020 Oct;158(4):e143-e146
pubmed: 32534909
Trauma Surg Acute Care Open. 2020 Apr 30;5(1):e000498
pubmed: 32411822
JAMA. 2020 Jun 23;323(24):2518-2520
pubmed: 32437497
Curr Med Sci. 2020 Apr;40(2):295-300
pubmed: 32232652
Lancet Infect Dis. 2020 Jun;20(6):697-706
pubmed: 32224310
N Engl J Med. 2020 Apr 16;382(16):1564-1567
pubmed: 32182409